Tolerogenic dendritic cells (tolDCs) are a promising treatment modality for diseases caused by a breach in immune tolerance, such as rheumatoid arthritis. Current medication for these diseases is dire
b, d, the corresponding Osteoarthritis Research Society International (OARSI) scores from normal, sham, veh (vehicle)-treated, and BNTA-treated rats at 4 w and 8 w (n = 8 for each group; nonpar